Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma

Trial Profile

The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Asthma
  • Focus Pharmacodynamics
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 15 Feb 2009 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov.
    • 20 May 2007 Results have been reported.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top